Literature DB >> 2842038

Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity.

S Rajagopalan1, P M Politi, B K Sinha, C E Myers.   

Abstract

Adriamycin is an anthracycline drug with a wide spectrum of clinical antineoplastic activity. However, the usefulness of the drug is limited by its dose-dependent cardiotoxicity. Adriamycin-stimulated free radical formation has been suggested as one of the mechanisms for its cardiotoxic effects. In order to evaluate this underlying mechanism, we have perfused rat hearts with Adriamycin, using a modified Langendorf technique, and the free radicals formed were analyzed by electron spin resonance spectroscopy using spin-trapping techniques. Our studies show that Adriamycin stimulated the formation of .OH in the heart, and the maximum .OH was formed with 1 microM of the drug. The addition of superoxide dismutase (600 units/ml) inhibited the hydroxyl radical formation by 2- to 3-fold, while catalase (550 units/ml) abolished it completely, showing the intermediacy of superoxide and H2O2. Furthermore, ICRF-187, an iron chelator and a cytotoxic drug, was also an effective inhibitor of .OH formation in the rat heart. The heart rate was not significantly modified by all the above experiments. This study demonstrates that Adriamycin stimulates the formation of .OH in the isolated rat heart and suggests that this mechanism may be significant in Adriamycin-induced cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2842038

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  Urinary biomarkers of oxidative status.

Authors:  Dora Il'yasova; Peter Scarbrough; Ivan Spasojevic
Journal:  Clin Chim Acta       Date:  2012-06-07       Impact factor: 3.786

Review 2.  Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?

Authors:  Douglas B Sawyer; Xuyang Peng; Billy Chen; Laura Pentassuglia; Chee Chew Lim
Journal:  Prog Cardiovasc Dis       Date:  2010 Sep-Oct       Impact factor: 8.194

3.  Urinary biomarkers of oxidative status in a clinical model of oxidative assault.

Authors:  Dora Il'yasova; Ivan Spasojevic; Frances Wang; Adviye A Tolun; Karel Base; Sarah P Young; P Kelly Marcom; Jeffrey Marks; Gabriel Mixon; Richard DiGiulio; David S Millington
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

4.  Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice.

Authors:  Yasumasa Ikeda; Ken-ichi Aihara; Masashi Akaike; Takashi Sato; Kazue Ishikawa; Takayuki Ise; Shusuke Yagi; Takashi Iwase; Yuka Ueda; Sumiko Yoshida; Hiroyuki Azuma; Kenneth Walsh; Toshiaki Tamaki; Shigeaki Kato; Toshio Matsumoto
Journal:  Mol Endocrinol       Date:  2010-05-25

5.  Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity.

Authors:  G Minotti; C Mancuso; A Frustaci; A Mordente; S A Santini; A M Calafiore; G Liberi; N Gentiloni
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

6.  The spectrum of mutations generated by passage of a hydrogen peroxide damaged shuttle vector plasmid through a mammalian host.

Authors:  E C Moraes; S M Keyse; M Pidoux; R M Tyrrell
Journal:  Nucleic Acids Res       Date:  1989-10-25       Impact factor: 16.971

Review 7.  Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging.

Authors:  Gurusher Singh Panjrath; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2006 May-Jun       Impact factor: 5.952

8.  Effects of melatonin in reducing the toxic effects of doxorubicin.

Authors:  Eser Oz; Mustafa N Ilhan
Journal:  Mol Cell Biochem       Date:  2006-04-20       Impact factor: 3.396

9.  Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells.

Authors:  Birandra K Sinha; Ashutosh Kumar; Suchandra Bhattacharjee; Michael G Espey; Ronald P Mason
Journal:  J Pharmacol Exp Ther       Date:  2013-09-18       Impact factor: 4.030

Review 10.  Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.

Authors:  Darren Lars Stirland; Joseph W Nichols; Seiji Miura; You Han Bae
Journal:  J Control Release       Date:  2013-10-02       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.